Update on the treatment of metastatic renal cell carcinoma

Table 1 Results from clinical trials

Checkmate 214	Nivolumab/ipilimumab (n = 425)	Sunitinib (n = 422)
Minimum follow-up	42 mo	42 mo
OS IP	52%; 47 (35.6-NE) mo	39% 26.6 (22.1-33.5) mo
ORR IP	42% (37-47)	26% (22-31)
CR IP	10%	1%
Checkmate 025	Nivolumab (n = 410)	Everolimus (n = 411)
Minimum follow-up	5 yr	5 yr
OS	26% (22.2-29.8)	18% (17.6-22.1)
ORR	23% (19-27)	4% (2-7)
mDOR	18.2 (12.9-25.8) mo	14 (8.3-19.2) mo
Keynote 426	Pembrolizumab/axitinib (n = 432)	Sunitinib (n = 429)
Minimum follow-up	23 mo	23 mo
OS	74%	66%
	HR: 0.68; 95%CI: 0.55-0.85; P < 0.001
PFS favorable risk	20.8 (15.4-28.8) mo	18 (12.5-20.8) mo
Checkmate 9ER	Nivolumab/cabozantinib (n = 323)	Sunitinib (n = 328)
Minimum follow-up	10.6 mo	10.6 mo
PFS	16.6 (12.5-24.9)	8.3 (7-9.7)
OS	NR (NE)	NR (22.6-NE)
ORR	55.7% (50.1-61.1)	27% (22.4-32.3)
CR	8%	4.6%
Adverse events grades 3-5	60.6%	50.9%

PFS: Progression free survival; OS: Overall survival; ORR: Objective response rate; CR: Complete response; mDOR: Median duration of objective response; NR: No results; NE: Not ended; HR: Hazard ratio; CI: Confidence interval; IP: Poor risk.